DBV Technologies (NASDAQ:DBVT) Shares Up 11.2% – Time to Buy?

DBV Technologies S.A. (NASDAQ:DBVT)’s share price was up 11.2% during trading on Tuesday. The company traded as high as $9.93 and last traded at $10.0630. 32,827 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 318,724 shares. The stock had previously closed at $9.05.

Analyst Ratings Changes

DBVT has been the topic of several research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a report on Thursday, October 15th. HC Wainwright restated a “buy” rating on shares of DBV Technologies in a research note on Friday, October 30th. Citizens Jmp cut their price target on DBV Technologies from $55.00 to $47.00 and set a “market outperform” rating for the company in a report on Thursday, October 29th. Citigroup reiterated a “market outperform” rating on shares of DBV Technologies in a research report on Thursday, October 29th. Finally, Guggenheim decreased their price objective on shares of DBV Technologies from $51.00 to $46.00 and set a “buy” rating on the stock in a report on Friday, October 30th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, DBV Technologies presently has an average rating of “Moderate Buy” and an average price target of $45.25.

DBV Technologies Stock Down 1.4%

The business’s fifty day moving average is $11.24 and its two-hundred day moving average is $16.81. The firm has a market cap of $616.20 million, a price-to-earnings ratio of -3.26 and a beta of -0.84.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Wednesday, October 28th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.41). The firm had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.56 million. DBV Technologies had a negative return on equity of 120.95% and a negative net margin of 5,392.17%. Research analysts forecast that DBV Technologies S.A. will post -2.22 EPS for the current year.

Institutional Investors Weigh In On DBV Technologies

Institutional investors and hedge funds have recently made changes to their positions in the company. Vivo Capital LLC increased its position in DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after purchasing an additional 205,943 shares during the period. ADAR1 Capital Management LLC bought a new stake in DBV Technologies during the 1st quarter worth about $21,159,000. Perceptive Advisors LLC acquired a new position in DBV Technologies during the 1st quarter valued at about $20,146,000. Atika Capital Management LLC lifted its position in DBV Technologies by 31.1% during the 1st quarter. Atika Capital Management LLC now owns 271,300 shares of the company’s stock valued at $5,667,000 after purchasing an additional 64,419 shares during the period. Finally, Elmind Capital LP acquired a new position in DBV Technologies during the 1st quarter valued at about $5,536,000. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.